Ideaya Biosciences Inc (IDYA) Peer Comparison

$39.71

$-0.26 (-0.65%)

As on 04-Sep-2026 13:35EDT

Market cap

$3,870 Mln

Revenue (TTM)

$234 Mln

P/E Ratio

--

P/B Ratio

3.4

Div. Yield

0 %

Edit

	Ideaya Biosciences Inc (IDYA)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Market cap ($ Mln)	3,870	16,765	16,261	13,492	12,332
Revenue ($ Mln)	234	2,782	1,054	2,436	1,284
Net Profit ($ Mln)	-175.02	491.50	755.85	860.62	-325.10
Net Margin (%)	-74.75	17.67	71.69	35.33	-25.32
RoE (%)	-15.75	110.09	--	42.98	-57.72
Price to Earnings	--	35.25	19.00	17.40	--
Price-To-Book	3.36	39.29	9.76	7.42	23.98

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Ideaya Biosciences Inc (IDYA)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Operating Revenue	234.13	2,782.29	1,054.37	2,435.92	1,283.94
Cost of Revenue	265.32	1,982.07	103.47	85.67	109.42
Gross Profit	-95.99	760.62	588.53	2,236.43	902.26
Operating Expenses	185.76	216.81	841.45	1,378.74	1,497.13
Operating Profit (EBIT)	-216.95	583.40	109.45	971.51	-322.62
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-175.02	598.92	101.11	1,035.47	-325.10
Provision for Tax	0.00	107.42	-654.74	174.84	0.00
Profit after Tax (Net Income)	-175.02	491.50	755.85	860.62	-325.10
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Ideaya Biosciences Inc (IDYA)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Shareholder's Funds	1,198.91	433.86	1,435.90	1,843.76	523.72
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	28.12	187.89	384.48	288.55	346.72
Current Liabilities	82.68	1,435.43	464.70	361.93	374.20
Total Liabilities	1,109.32	1,975.47	1,302.02	2,844.42	1,259.59

Assets ($ Mln)

	Ideaya Biosciences Inc (IDYA)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Non-Current Assets	445.67	1,006.90	895.24	1,243.41	45.47
Current Assets	864.03	1,050.29	1,389.84	1,250.82	1,199.18
Total Assets	1,109.32	1,975.47	1,302.02	2,844.42	1,259.59
Total Debt*	29.31	120.10	449.89	165.93	347.75
Net Current Assets	781.35	-385.14	0.00	888.90	824.98

Cashflow ($ Mln)

	Ideaya Biosciences Inc (IDYA)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Cash From Operating Activities	-71.10	713.22	51.77	884.27	-189.55
Cash Flow from Investing Activities	69.98	-31.14	-8.15	350.44	32.32
Cash from Financing Activities	29.78	-860.39	34.89	-969.59	255.98
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Ideaya Biosciences Inc (IDYA)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
ROCE (%)	-10.68	53.56	-30.01	32.82	-31.49
ROE (%)	-15.75	110.09	163.18	42.98	-57.72
ROA (%)	-14.06	15.64	26.53	29.32	-22.97
EBIT Margin (%)	-92.66	21.13	5.73	31.04	-18.97
Net Margin (%)	-74.75	17.67	71.69	35.33	-25.32
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Ideaya Biosciences Inc (IDYA)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Revenue Growth (%)	3,244.67	24.67	114.85	9.23	149.04
EBIT Growth (%)	38.94	18.70	136.39	-3.99	9.16
Net Profit Growth (%)	47.25	17.50	378.76	42.89	-15.32
EPS Growth (%)	48.68	26.84	353.27	50.42	-0.64
Book Value Growth (%)	20.06	164.02	816.12	-0.70	-42.66

Valuation Ratios

	Ideaya Biosciences Inc (IDYA)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Price / Earnings	-26.93	36.06	-59.76	15.79	-45.32
Price / Book Value	2.99	35.44	-80.42	5.72	21.68
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-15.84	28.08	-121.54	12.44	-47.02
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Ideaya Biosciences Inc (IDYA)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Debt to Equity	0.00	0.00	0.00	0.00	0.65
Short term debt to equity ratio	0.00	0.00	0.05	0.00	0.00
Current Ratio	10.45	0.73	2.99	3.46	3.20
Quick Ratio	10.45	0.73	2.32	3.38	2.94
Interest Coverage	--	--	1.62	--	-19.80

Operating Efficiency Ratios

	Ideaya Biosciences Inc (IDYA)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Debtors to sales (%)	6.58	15.88	21.25	13.74	14.98
Asset Turnover	0.19	0.89	0.37	0.83	0.91
Receivable days	4.99	50.42	85.52	43.48	35.88
Inventory Days	--	--	1,056.70	96.17	354.23
Payable days	19.15	6.26	331.01	147.97	300.79
Cash Conversion Cycle	--	--	811.21	-8.32	89.33

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly